KR20030062139A - Oral mucoadhesive film - Google Patents

Abstract

PURPOSE: A film applicable to the oral mucosa comprising two layers such as a protective layer and an adhesive layer which contain a drug is provided to effectively delivery the drug without changing the formulation. The film causes no foreign body sensation when applied to oral mucosa and has excellent convenience and efficiency in the preparation process. CONSTITUTION: An oral mucoadhesive film comprises: an adhesion layer containing 5 to 80% by weight of each of a polyacrylic acid-based polymer and a cellulose-based polymer, 5 to 70% by weight of poloxamer, 0.05 to 20% by weight of a drug absorbable through the oral mucosa and 0.1 to 10% by weight of a plasticizer; and a protective layer containing 5 to 50% by weight of a water-insoluble, water-impermeable polymer and 0.1 to 10% by weight of a plasticizer. The film has a thickness of 50 to 300 microns.

Description

Oral mucoadhesive film preparation {Oral Mucoadhesive Film}

The present invention relates to a new oral mucoadhesive film formulation. More specifically, the present invention is composed of two layers of a protective layer composed of an adhesive layer comprising a polyacrylic acid polymer, a cellulose polymer, a poloxamer and a therapeutic drug and a plasticizer, and a water insoluble and water impermeable polymer and a plasticizer. It relates to an oral mucoadhesive film formulation and a method for producing the same.

Most of the mucous membranes present in the gastrointestinal tract and oral cavity, unlike the skin, are easy to absorb the active ingredient, so it is quickly absorbed and relatively high molecular weight substances such as drugs with peptide structure tend to be absorbed. Its use value is very high as a route. In particular, drugs absorbed through oral mucosa or gums are not effective for gastrointestinal disorders and hepatic first-pass effects, and can be effectively used for drugs intended for systemic action along with local drug delivery to oral diseases such as local anesthesia and stomatitis. It has features that can be.

Gel formulations, one of the drug delivery formulations using oral mucosa, are commonly used for the treatment of oral ulcers, herpes simplex, but they are easily mixed and swelled by saliva, resulting in a short retention time of the formulation. More to swallow. Tablet-type formulations have a prolonged retention time of the formulation in the mucosa, but there is a foreign body feeling by the size and thickness thereof, and when attached to the mucosa, there is a risk of being swallowed with the food by being affected by food intake. However, the film-type formulations have a low foreign body feeling when attached to the oral mucosa, are convenient to use, and can maintain adhesion without deformation of the form for a certain period of time when the drug is delivered. It may be referred to as a formulation suitable for attachment.

In order to deliver the drug through the oral mucosa, the drug-containing formulation must maintain its shape for a certain period of time. However, most of the mucoadhesive polymers used in these oral mucoadhesive film-type preparations rapidly swell or dissolve upon contact with moisture. Because of the short time to stay on the mucous membrane, drug delivery is not continuous. In addition, the diffusion rate of the active ingredient changes with the swelling of the polymer, making it difficult to predict the transfer rate.

Of these, polyacrylic acid and cellulose-based polymers have excellent mucoadhesive properties (J. Pharm. Sci., 89 (7), 850-866 (2000)), but maintain swelling or solubility by saliva for a long time. (US Patent Nos. 4,292,299, 4,740,365, and European Patent No. 654,261) and in the case of having an adhesive layer composed of sodium carboxymethyl cellulose, polyacrylic acid and hydroxyethyl cellulose (US Pat. No. 6,159,498). In addition, the retention time of the formulation was not less than 1 hour, and the drug was not delivered efficiently due to the gel state after adhesion, and even when hydroxypropyl methyl cellulose was used (US Pat. No. 5,948,430), the water solubility was high. There was a drawback that could not be applied to formulations requiring adhesion.

Therefore, in the development of oral mucoadhesive formulation, the introduction of a new mucoadhesive polymer that can maintain the form and adhesion of the formulation until the drug is urgently needed. Oral mucoadhesive preparation should be easy to use and minimize patient's sense of foreign body after attachment, and maintain adhesive strength without deformation of shape for a certain time for effective drug delivery. .

The adhesive layer, the impermeable layer, the drug layer and the control layer is composed of four or three layers, each layer is made to dry to a certain weight, then laminated the layers in sequence and completely dried (US Patent No. 5,196,202) No. 4,900,552) has been developed, but its manufacturing process is cumbersome, and it is difficult to control dry weight and lamination during actual production, resulting in low efficiency of the manufacturing process, and due to different hydration rates of each layer, Due to the deformation, drug loss occurred and the thickness of the film was about 800 μm, which is thicker than that of the conventional oral mucoadhesive film preparation.

On the other hand, in the case of a monolayer film, since the mucosal adhesion layer is directly exposed to intraoral moisture such as saliva, the formulation retention time is affected, and thus the use of the monolayer film is limited to fast-acting drug delivery (US Pat. No. 5,948,430).

In addition, the film is composed of two layers, a protective layer and an adhesive layer that serve as protection and support, to extend the maintenance time of the formulation and to increase the mucosal absorption efficiency of the drug, thereby improving the problems of the single layer and the multilayer film. However, in the case of a two-layer film composed of an adhesion layer such as vinyl acetate and polyacrylic acid and a protective layer such as polyethylene and aluminum (US Pat. No. 5,137,729), an interlayer separation phenomenon between the adhesion layer and the protection layer and foreign material feeling at the time of adhesion are felt. And water-insoluble substances such as ethyl cellulose (EC), hydroxypropyl cellulose phthalate (HPC-P) and cellulose acetate phthalate (CA-P), as protective layer materials (US Pat. No. 4,876,092). No.) The possibility of separation of the two layers due to the low affinity between layers between the protective layer and the adhesion layer and the rate of hydration caused by saliva after attachment Many. Therefore, the type of mucoadhesive polymer used for the protective layer and the adhesive layer and the interlayer affinity between the adhesive layer and the protective layer are important issues to be considered first in the formulation maintenance.

As a method for increasing the interlayer affinity of the film, there is a method in which a plasticizer such as polyhydric alcohol is added to the adhesion layer and the protective layer, but it is difficult to maintain the formulation for a long time due to the swelling and high solubility of the mucoadhesive polymers used in the adhesion layer. (Patent No. 2000-31828) There is also a method of adding water-insoluble titanium carbonate and talc to the adhesion layer to maintain the form of the formulation, but the flexibility of the adhesion layer film is reduced, the interlayer between the adhesion layer and the protective layer. Affinity is reduced and there is a disadvantage (Separated Patent No. 1997-9794) that the separation between layers.

In order to solve the problems of the above-described oral mucoadhesive film formulations, the present inventors have excellent mucoadhesive properties but cannot maintain long-term adhesive force due to swelling or dissolution by saliva. In view of the fact that it is possible to control the swelling and solubility by the addition of the saliva to prepare a new oral mucoadhesive film formulation as follows.

The purpose of the present invention is to maintain the adhesion for a long time without change of the formulation for a certain time for more effective drug delivery to the oral mucosa. To develop an oral mucoadhesive film formulation.

1 is a diagram showing a cross section of an oral mucoadhesive film formulation consisting of an adhesion layer and a protective layer containing a drug.

2 is a graph showing the results of drug dissolution experiments in Example 1 (●), Example 2 (■), Comparative Example 1 (◆), and Afta Tablet (▲).

The present invention is an oral mucoadhesive film preparation consisting of an adhesion layer and a protective layer containing a therapeutic drug, and a water-insoluble and water-impermeable composition consisting of ethyl cellulose (EC), polyurethane (PU), polyethylene (PE) or polyester. A protective layer consisting of a polymer and a plasticizer and hydroxypropyl cellulose (HPC), hydroxymethyl cellulose (HMC), hydroxyethyl cellulose (HEC), hydroxypropyl ethyl cellulose (HPEC) and hydroxypropyl methyl cellulose It consists of an adhesion layer which has mucoadhesiveness containing polyacrylic-acid polymers, such as cellulose polymers, such as (HPMC), polyacrylic-acid polymers, such as carbomer and polycarbophil, and a poloxamer and a plasticizer. At this time, the adhesion layer is a film-type drug-containing layer that can be attached to the oral mucosa, which is attached to the oral mucosa to deliver the drug, and the protective layer is that the drug contained in the adhesion layer is lost or rapidly swelled by saliva and easily falls from the oral mucosa. prevent.

As the polyacrylic acid-based polymer blended in the adhesive layer, carbomers, polycarbophiles or mixtures thereof having excellent mucoadhesive properties may be used. The polycarbophils are acrylic acid polymers crosslinked by divinyl glycol and carbomers are allyl sucrose or Carbopol 980, 934, 940, 941, 934P, 971P, 974P, 981, 1342, 1382, 2984, 5984EP and Noveon AA-1, polymers polymerized by allylpentaerythritol, sold under the trade names Carbopol and Noveon. , CA-1, CA-2 and the like can be selected and used, of which Carbopol 934P or Carbopol 971P is preferred.

Cellulose-based polymers have excellent film-forming ability and are used as binders and film coating agents for tablets. Hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl ethyl cellulose or hydroxypropyl methyl cellulose are used. Among these, the use of hydroxypropylethyl cellulose or hydroxypropyl methyl cellulose is preferable.

Poloxamer is a copolymer of polyethylene glycol and polypropylene glycol, which is used as an emulsifier and dissolution aid, and has various gel formation characteristics depending on its type, concentration, and mixing ratio. Poloxamer 124, 188, 338, or 407 can be used. The use of poloxamer 188 or 407 is preferred.

Plasticizers that can be used in the adhesion layer include castor oil or polyethylene glycol (PEG), but polyethylene glycol is preferred.

Drugs to be added to the adhesion layer include all drugs that can be absorbed into the oral mucosa, for example, oral diseases treatment agents such as triamcinolone acetonide or glycyrrhetinic acid, anti-inflammatory agents such as ketoprofen or pyricampam, and diphenhydra. Antihistamines such as min or chloropheniramine, hormones such as estradiol or testosterone, antihypertensive agents such as clonidine or propranolol, bronchodilators such as theophylline or terbutalin, and anesthetic drugs such as lidocaine or dibcaine. Among them, drugs with high physiological activity that can be administered in relatively small amounts, drugs that are easily metabolized when used as oral administration agents, and those with digestive tract disorders are preferable.

As the water-insoluble and water-impermeable polymer contained in the protective layer of the present invention, polyester, polyurethane, polyethylene, or ethyl cellulose may be used, and among these, the use of polyurethane or ethyl cellulose is preferable. Ethyl cellulose is used as a water-insoluble coating for tablets and granules for the purpose of controlling release, masking taste, and improving stability.

Plasticizers that can be used in the protective layer include triethyl citrate (TEC), castor oil, polyethylene glycol and the like, but polyethylene glycol and triethyl citrate are preferred.

The present invention is a two-layer oral mucoadhesive film formulation consisting of an adhesion layer and a protective layer as shown in FIG.

In order to manufacture the adhesion layer excellent in film formation property and mucoadhesive property in this invention,

First, a film was prepared by preparing a solution in which a crosslinked polyacrylic acid polymer and a cellulose polymer having excellent mucoadhesion were prepared. However, it was possible to produce a homogeneous film with this mixed solution, but the high swelling or solubility of the film by saliva decreased the efficiency of drug delivery through the mucosa and the high viscosity made it difficult to produce a high concentration of solution in large quantities. Due to the lack of flexibility, foreign body felt when attached to the mucous membrane.

Accordingly, the present inventors can add a poloxamer to the polymer mixed solution to prepare an adhesive layer, and thus the composition can be manufactured even at a low temperature, and the viscosity of the mixed solution is low, which facilitates the film manufacturing process, as well as swelling due to the saliva of the produced film. Its solubility was reduced, allowing long-term adhesion to the oral mucosa.

As a result of measuring the change in the water content of the film prepared after the addition of poloxamer, it was found that the water content of the film decreases as the amount of poloxamer in the composition increases, thus increasing the shape retention time in the aqueous solution (Experimental Example 2). . This may be because poloxamers form hydrogen bonds with carbopol or hydroxypropylmethylcellulose to form a more compact three-dimensional network.

Hydrogen bond formation due to the addition of poloxamer was an infrared spectroscopy spectrum (IR), the flexibility change of the film was confirmed by using a dynamic viscoelasticity meter (DMTA). That is, as the amount of poloxamer in the composition increases, the characteristic peak of the poloxamer in the infrared spectroscopy spectrum due to hydrogen bond formation was changed to a short wave number, and the glass transition temperature, which is the temperature at which the molecules move, was hydroxypropylmethyl. Lowering than that of the cellulose and carbopol mixture was considered to increase the flexibility of the film by that amount (Experimental Example 3).

The adhesion layer needs the ability to control the dissolution of the drug absorbed through the mucosa along with the mucoadhesiveness. For this purpose, proper blending of the polymers mentioned above is important. The polyacrylic acid polymer and the cellulose polymer are added in an amount of 5 to 80% by weight, preferably 20 to 50% by weight. If the content is less than 5% by weight, the viscosity of the solution is low at the time of manufacture, so that it is impossible to manufacture a film of a certain thickness, which may reduce the adhesion of the film.

The poloxamer is added 5 to 70% by weight, but preferably 20 to 50% by weight. If it is 5% by weight or less, the solubility and swelling degree of the film is increased, so it is difficult to maintain the shape.

The mixed solution is prepared so that the concentration of the above three polymer solutions is 5 to 20% by weight of the total weight of the adhesion layer. The preferred blending ratio of the polymers is poloxamers and crosslinked polyacrylic acid and poloxamers and hydroxypropylmethylcellulose. It is added in the ratio of 1: 1: 1: 1.5. In the above concentration range, it is easy to control the film thickness and film drying time during film production.

The drug added to the adhesion layer is added at 0.05 to 20% by weight of the total weight of the adhesion layer, and if it is 20% by weight or more affects the viscosity of the adhesion layer solution, film production is not easy.

In the protective layer which serves to protect the adhesion layer from saliva, the water-insoluble and water-impermeable polymer is added in an amount of 5 to 50% by weight, preferably 10 to 30% by weight of the total weight of the protective layer. If it is 5% by weight or less, the fluidity of the solution is too high to produce a film, and if it is 50% by weight or more, it is difficult to produce a film of a certain thickness.

In order to maintain the shape of the oral mucoadhesive film composed of an adhesive layer having a mucoadhesive layer and a protective layer having water insoluble and water impermeable characteristics, long-term bonding force between the two layers is also important.

In the present invention, a film was prepared by adding various kinds of plasticizers to the adhesion layer and the protective layer, and an optimum plasticizer for each component of the layer was selected in consideration of the adhesion between the two layers and the affinity between the two layers. Castor oil and polyethylene glycol (PEG) may be used as the adhesion layer, and triethyl citrate (TEC), castor oil or polyethylene glycol (PEG) may be used as the protective layer.

When triethyl citrate was added to the adhesion layer, film formation was impossible, and when caster oil and polyethylene glycol were added to the adhesion layer solution, the film formability and flexibility were better, and polyethylene glycol was better than when caster oil was used. Adhesion was better when added.

Most preferably, polyethylene glycol was added to the adhesion layer, and triethyl citrate was added to the protective layer, and the adhesion of the mucosa to the oral mucosa was excellent.

The amount of plasticizer added to the adhesion layer and the protective layer at this time is 0.1 to 10% by weight and preferably 2 to 8% by weight of the total weight of the adhesion layer or the protection layer, respectively. If it is more than 10% by weight affects the interlayer film formation and drying process of the adhesion layer and the protective layer is not easy to manufacture a film.

Method for producing an oral mucoadhesive film formulation having such characteristics is as follows.

First, 5 to 80% by weight of polyacrylic acid polymer, 5 to 70% by weight of poloxamer and 5 to 80% by weight of cellulose polymer are dissolved in a mixture of water and ethanol with respect to the total weight of the adhesion layer polymer. Prepare a homogeneous coating solution having a concentration of 5 to 20% by weight of the total weight of the adhesion layer, and then add 0.1 to 20% by weight of the drug and 0.1 to 10% by weight of the plasticizer of the adhesion layer. Dissolve to prepare a homogeneous adhesion layer solution.

Separately, a homogeneous coating solution is prepared by dissolving 5 to 50% by weight of the water-insoluble and water-impermeable polymer and 0.1 to 10% by weight of the plasticizer of the protective layer in ethanol.

First, the adhesive layer solution is removed from the air bubbles, and then coated on a release film using a coater (Laboratory Drawdown Coater LC-100, Chem Instruments) and dried to obtain an adhesive layer film.

Thereafter, the protective layer solution also removes the bubbles therein, and is then coated on the adhesive layer film using a coater and then dried to prepare a film-type oral mucoadhesive film formulation composed of the adhesive layer and the protective layer.

When the dry oral mucoadhesive film formulation is dried, the total thickness is 30 to 500 μm, and the thickness of the adhesive layer and the protective layer is 20 to 300 μm and 10 to 200 μm, respectively, and the preferred total thickness is 50 to 300 μm. If the total thickness is less than 30㎛ concern about maintaining the form of the formulation and smooth drug dissolution to the mucous membrane, if more than 500㎛ can feel a foreign object.

In addition, the present invention may further include conventional lubricants, disintegrants, pigments and the like depending on the nature of the formulation.

Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited thereto.

Examples 1-19

An adhesion layer and a protective layer solution were prepared in the same composition as Tables 1 and 2, respectively.

First, a homogeneous coating solution was prepared by dissolving polymer materials such as polyacrylic acid polymer, poloxamer and cellulose polymer in water and ethanol mixed solvent, and then adding and dissolving the drug and plasticizer of the adhesion layer to homogeneous adhesion layer solution. Was prepared.

Separately, the water-insoluble and water-impermeable polymer and the plasticizer of the protective layer were dissolved in ethanol to prepare a homogeneous coating solution.

First, the adhesive layer solution was removed from the air bubbles, and then coated on a release film using a coater (Laboratory Drawdown Coater LC-100, Chem Instruments) and dried to obtain an adhesive layer film.

Thereafter, the protective layer solution is also removed from the air bubbles, coated with a coater on the adhesive layer film, and then dried to prepare a film-type oral mucoadhesive film formulation containing 25 μg of triamcinolone acetonitrile, which is composed of an adhesive layer and a protective layer. Prepared. At this time, the thickness of the film was 60 to 100 µm.

Examples 1-10 Compositions Example Composition One 2 3 4 5 6 7 8 9 10 Adhesion layer Triamcinolone Acetonide 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Poloxamer 407 3.0 4.0 4.0 3.0 3.0 Poloxamer 188 4.5 4.0 2.2 2.5 2.4 Carbopol 971P 3.5 4.5 4.5 5.0 4.5 Carbopol 934P 4.2 3.5 2.8 3.5 3.0 Hydroxypropylmethylcellulose 3.5 4.5 5.0 3.7 4.5 5.5 4.5 3.1 3.1 2.6 Polyethylene glycol 3.9 3.9 4.0 6.6 1.9 2.3 3.5 4.0 7.2 3.9 water 43.0 41.5 41.2 41.2 43.5 41.3 41.7 43.9 41.8 44.0 ethanol 43.0 41.5 41.2 41.2 43.5 41.3 41.7 43.9 41.8 44.0 Gross weight (g) 100 100 100 100 100 100 100 100 100 100 Protective layer Ethyl Cellulose 15 12 17 22 13 20 12 17 21 16 Triethyl Citrate 4.0 3.5 4.2 4.0 3.2 2.9 3.3 4.2 4.3 3.5 ethanol 81 84.5 78.8 74.0 83.8 77.1 84.7 78.8 74.7 80.5 Gross weight (g) 100 100 100 100 100 100 100 100 100 100

Examples 11-19 Compositions Example Composition 11 12 13 14 15 16 17 18 19 Adhesion layer Triamcinolone Acetonide 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Poloxamer 407 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 Poloxamer 188 Carbopol 971P 1.75 1.75 1.75 1.75 1.75 1.75 Carbopol 934P 1.75 Cabopol 940 1.75 Cabopol 974P 1.75 Hydroxypropylmethylcellulose 1.75 1.75 1.75 1.75 1.75 1.75 1.75 1.75 1.75 Polyethylene glycol 1.9 0.9 0.9 2.9 1.9 1.9 1.9 1.9 1.9 water 46.5 47.0 47.0 46.0 46.5 46.5 46.5 46.5 46.5 ethanol 46.5 47.0 47.0 46.0 46.5 46.5 46.5 46.5 46.5 Gross weight (g) 100 100 100 100 100 100 100 100 100 Protective layer Polyurethane 15 12 17 22 13 20 12 17 21 Triethyl Citrate 4.0 3.5 4.2 4.0 3.2 2.9 3.3 4.2 4.3 ethanol 81 84.5 78.8 74.0 83.8 77.1 84.7 78.8 74.7 Gross weight (g) 100 100 100 100 100 100 100 100 100

Comparative Examples 1 to 12 Compositions Example Composition One 2 3 4 5 6 7 8 9 10 11 12 Adhesion layer Triamcinolone Acetonide 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Poloxamer 407 8.4 12.5 10 2 2 Poloxamer 188 9.0 7.4 7.9 Carbopol 971P 3.5 2.5 1.5 One Carbopol 934P 2.0 3.5 2.5 Hydroxypropylmethylcellulose 3.5 9.9 7.4 3.0 5.0 1.0 One Polyethylene glycol 4.0 4.0 4.0 6.6 1.9 2.3 3.5 4.0 7.3 4.0 4.0 3.9 Castor oil Triethyl Citrate water 46.2 42.5 46.2 39.4 42.3 40.6 43.2 45.2 40.1 44.0 45.7 46.0 ethanol 46.2 42.5 46.2 39.4 42.3 40.6 43.2 45.2 40.1 44.0 45.7 46.0 Gross weight (g) 100 100 100 100 100 100 100 100 100 100 100 100 Protective layer Ethyl Cellulose 18 18 13 21 17 23 14 12 18 23 18 18 Castor oil Polyethylene glycol Triethyl Citrate 4.0 3.5 4.2 4.0 3.2 2.9 3.3 4.2 4.3 3.5 4.0 4.0 ethanol 78.0 78.5 82.8 75.0 79.8 74.1 82.7 83.8 77.7 73.5 78 78 Gross weight (g) 100 100 100 100 100 100 100 100 100 100 100 100

Comparative Examples 13-22 Composition Example Composition 13 14 15 16 17 18 19 20 21 22 Adhesion layer Triamcinolone Acetonide 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Poloxamer 407 3.0 4.0 4.5 3.0 3.0 Poloxamer 188 4.7 4.0 2.2 2.5 2.4 Carbopol 971P 3.5 4.4 5.9 5.2 4.5 Carbopol 934P 4.1 3.5 2.8 3.5 3.0 Hydroxypropylmethylcellulose 3.5 4.5 5.7 3.7 4.5 4.9 4.5 3.1 3.1 2.6 Polyethylene glycol 4.0 4.0 7.2 Castor oil 3.9 4.0 6.7 2.3 3.5 3.9 Triethyl Citrate 1.9 water 43.0 41.5 39.9 41.2 43.5 41.4 41.7 43.9 41.8 44.0 ethanol 43.0 41.5 39.9 41.2 43.5 41.4 41.7 43.9 41.8 44.0 Gross weight (g) 100 100 100 100 100 100 100 100 100 100 Protective layer Ethyl Cellulose 15 12 17 22 13 20 12 17 21 16 Castor oil 3.5 4.0 3.2 2.9 4.3 3.5 Polyethylene glycol 4.2 3.3 4.2 Triethyl Citrate 4.0 ethanol 81.0 84.5 78.8 74.0 83.8 77.1 84.7 78.8 74.7 80.5 Gross weight (g) 100 100 100 100 100 100 100 100 100 100

Comparative Examples 1 to 12

The composition is different from the examples, but after the adhesion layer solution and the protective layer solution was prepared in the same manner using a coater to prepare a film consisting of the adhesion layer and the protective layer (Table 3).

Comparative Examples 13 to 22

Only the plasticizers of Examples 1 to 10 and the other plasticizers were different, and the same composition was used to prepare films consisting of an adhesive layer and a protective layer in the same manner (Table 4).

Control group 1

Triamcinolone the adhesion layer as a product in the market acetonide, hydroxypropyl cellulose and carboxy vinyl-containing and protective layer of polymer, etc., hydroxypropyl cellulose and carboxymethyl an oral mucosal patch containing cellulose and calcium agent aphthous chijeong ^® (moving picture drugs Industrial Co., Ltd.) was used as a control.

Control 2

As a commercially available product, Inert Plasta (available from Water Chemicals Co., Ltd.), an oral mucosa patch containing triamcinolone acetonide as a main ingredient, was used as a control.

Control group 3

As a commercially available product, oral mucosa patch 大 일본 (Daily Pharmaceutical Co., Ltd.), which is an oral mucosa patch containing root root extract and enoxolone as main ingredients, was used as a control.

Experimental Example 1 Measurement of Adhesion and Mechanical Strength

The film samples prepared in Examples and Comparative Examples were attached to a polypropylene plate and subjected to a constant pressure for 3 minutes, and then measured the force when falling from the polypropylene plate using Instron (AGS-5000D, Shimadzu). Indicated.

Adhesion and Mechanical Strength of Film Composition Adhesion (N) Mechanical strength (N) Remarks (polymer concentration,%) Example 10 Comparative Example 10 Comparative Example 22 6.52.83.3 1.92-- 87.98 Example 1 Comparative Example 2 Comparative Example 13 7.84.04.7 2.01-- 1010.910 Example 5 Comparative Example 4 Comparative Example 17 8.04.3- 2.07-- 1114.511 Example 6 Comparative Example 5 Comparative Example 18 8.56.35.6 2.13-- 1513.414.8

As a result of measuring the adhesive force of each film, the adhesion increased as the concentration of the mucoadhesive polymer in the adhesive layer increased from 8 to 10%, but there was no significant change in the adhesive force above 10%. And even if the concentration of the polymer is similar, the film prepared from the composition consisting of three polymers, such as poloxamer, carbopol, hydroxypropyl methyl cellulose (Examples 10, 1, 5 and 6), the polymer alone or two Adhesion increased, respectively, than the films prepared in the composition (Comparative Examples 10, 2, 4, and 5). In addition, as a plasticizer, the films prepared from the composition (Examples 10, 1, 5, and 6) containing polyethylene glycol in the adhesion layer and triethyl citrate in the protective layer were caster oil and triethyl ether in the adhesion layer and the protective layer. It was found that the mucoadhesive force was superior to the composition containing the citrate (Comparative Examples 13, 18 and 22). In addition, Comparative Example 17, which is a composition in which triethyl citrate is included in the adhesive layer, was not able to manufacture a film.

Therefore, the interlayer affinity was the best when polyethyleneglycol was added to the adhesion layer and triethylcitrate as the plasticizer to the protective layer. This is because polyethylene glycol is structurally similar to poloxamers in the adhesion layer and triethyl citrate in the ethylcellulose in the protective layer.

The mechanical strength also did not change significantly depending on the concentration of the polymer in the adhesion layer. Films containing polyethylene glycol and triethyl citrate (Examples 10, 1, 5, and 6) as plasticizers were applied to the adhesion layer and the protective layer, respectively. Except mechanical strength could not be measured.

Experimental Example 2. Measurement of water content and shape holding time of film

The water content and shape retention time of the film in the phosphate buffer solution of pH 6.8 are shown in Table 6.

The water content of the film was calculated using the following formula.

Water content (wt .-%) = [(weight of film at swelling-weight of film at drying) / weight of film at swelling] × 100

As the proportion of poloxamer in the composition increases, the water content decreases, but the shape retention time of the formulation increases.

Water content and shape holding time of film Composition Water content (wt .-%) Shape hold time (hr) Remarks (poloxamer,%) Comparative Example 8 Comparative Example 11 Example 1 Comparative Example 12 Control Group 1 Control Group 2 897845758496 6.28.2> 249.17.84.5 -232--

Control Group 1: Afta Tablets

Control Group 2: Inner Plata

Experimental Example 3 Infrared Spectroscopy (IR) and Dynamic Viscoelasticity Analyzer (DMTA)

FT-IR (M.Series, Midac Corporation, USA) was used for the film, and the glass transition temperature (Tg) was 5 ℃ / min in the temperature range from room temperature to 300 ℃. Was measured. As a result, as the proportion of poloxamer in the composition increased, the peak generated by hydrogen bonding of carboxyl group and poloxamer of carbopol in infrared spectroscopy shifted from 1110 to 1107 cm ^-1 shortwave number, and hydroxypropylmethylcellulose The glass transition temperature in the and Carbopol mixture also decreased from 190 to 170 ° C (Table 7).

Changes in wavenumber and glass transition temperature due to hydrogen bonding of films Composition Frequency (cm ^-1 ) Tg (℃) Remarks (poloxamer,%) Comparative Example 8 Comparative Example 11 Comparative Example 12 Example 1 1110--1107 190180180170 -223

Experimental Example 4 Bioadhesion Test

Rectal mucosa of rabbits was attached to both vials of the bioadhesion measuring device, a film was attached between them, and the weights were placed in order to make the weight of the weight when the vial fall (HGChio, JHJung, JMRyu). , SJYoon, YKOh and CKKim, Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository, Int. J. Pharm., 165, 33-44, 1998) The results are shown in Table 8.

Bioadhesion of Film Composition Bioadhesive force (dyne / cm ² ) × 10 ² Remarks Polymer (% by weight) Plasticizer (adhesive layer, protective layer) Example 16 Example 10 Example 1 Example 3 6.278.5710.3311.02 581013.5 PEG, TECPEG, TECPEG, TECPEG, TEC Comparative Example 14 Comparative Example 13 Comparative Example 15 Comparative Example 19 Comparative Example 16 8.06.676.936.144.87 12.91016.11310.8 PEG, COCO, TECCO, PEGCO, PEGCO, CO

* PEG: polyethylene glycol

TEC: Triethyl Citrate

CO: Caster Oil

When polyethylene glycol and triethylcitrate were respectively added as a plasticizer to the adhesion layer and the protective layer, the bioadhesion was increased from 6.27 to 11.02 as the concentration of the polymer included in the adhesion layer was increased. . However, as a plasticizer, polyethylene glycol and castor oil (Comparative Example 14), castor oil and triethyl citrate (Comparative Example 13), caster oil and polyethylene glycol (Comparative Examples 15 and 19) or caster oil and castor oil were added ( Comparative Example 16) In the case of polyethylene glycol and triethyl citrate were added to the adhesion layer and the protective layer, respectively, the value was lower than that of the film.

Experimental Example 5 Measurement of Attachment Time

The films prepared in Examples and Comparative Examples were cut to a certain size and attached to glass walls of 5, 7.5 and 10 cm height of the dissolution test vessel, and the pH 6.8 was applied at 37 ± 0.5 ° C. by applying the second method in the dissolution test method. 900 mL of the phosphate buffer solution was observed by rotating the paddle at a speed of 100 rpm. The control group was also measured in the same manner and the results are shown in Table 9.

Measurement of film adhesion time Composition Film thickness (㎛) Attachment time (hr) Example 1 Example 9 Comparative Example 20 Comparative Example 16 Comparative Example 14 Comparative Example 19 Comparative Example 1 Comparative Example 2 Comparative Example 5 Control Group 1 Control Group 2 75.377.272.669.771.474.865.370.769.31,100100 > 24> 2413.76.015.214.76.0713.412.07.84.5

In the film prepared by using polyethylene glycol and triethyl citrate as a plasticizer, the adhesion time was very long (more than 24 hours) when all three polymers were included in the adhesion layer (Examples 1 and 9). It can be seen that the adhesion time is longer than that of the polymers alone or in combination of two (Comparative Examples 1, 2 and 5). The adhesion time was 6.0-24 hours or more, depending on the type of plasticizer, and various results were shown, which showed a tendency to be consistent with the results of adhesion and bioadhesive force.

Experimental Example 6 Drug Dissolution Experiment

Each film-type oral mucoadhesive agent was attached to a cellulose membrane, followed by dissolution experiment using a diffusion cell. Phosphate buffer (pH 6.8) and ethanol mixture (3: 2 (v / v)) were used as the eluent and sampled at regular intervals to evaluate the drug release from each formulation by HPLC. As a result of comparing the drug dissolution results of the commercially available control formulation 1 with the film-form formulation of the present invention, the drug formulations of the present invention showed a preferable drug dissolution result compared to the comparative example or a commercial product (control group) (see FIG. 2).

Experimental Example 7 Evaluation of Adhesion in Oral Mucosa

In order to evaluate the adhesion of the formulation in the actual oral mucosa, after measuring the time to drop after attaching the film-form formulation on the inside of the lower lip of the volunteer, the results are shown in Table 10. In addition, when applied to the oral mucosa, the value for feeling was evaluated by displaying the following four steps.

1. I do not feel much.

2. There is a little bit of foreign body feeling.

3. There is a sense of foreign object, which is unpleasant.

4. Other (I can feel irritation and pain)

Evaluation of adhesion of film on oral mucosa Composition Attachment time (hr) Feeling Example 1 Example 3 Example 8 Comparative Example 1 Comparative Example 13 Comparative Example 22 Control Group 1 Control Group 2 Control Group 3 3.84.23.01.21.71.43.21.53.5 1.41.71.81.51.61.92.82.72.1

In the adhesion time, Example 3 was the longest with 4.2 hours, and Example 1 and 8 also showed results of more than 3 hours in both 3.8 and 3.0 hours, respectively. However, when the film contains the carbopol alone as a mucoadhesive polymer (Comparative 1), and the plasticizer of the adhesion layer and the protective layer is castor oil and triethyl citrate, respectively (Comparative Example 13), the adhesion time is 1.2 to It can be seen that 1.7 is shorter than the above example compositions. The aptachi tablet used as the control group 1 had an attachment time of 3.2 hours, the control group 2 had 1.5 hours of the inner plaster, and the control group had three stomatitis patches 3.5A.

Each control group felt a foreign body when attached to the oral mucosa while the films prepared in Examples and Comparative Examples of the composition of the present invention could not feel the foreign body.

In addition, the compositions of the present invention were also excellent in the initial adhesion to the oral mucosa and there was no phenomenon that the polymer swells off or remains on the oral mucosa even during or after adhesion to oral mucosa. However, in the control group 1 and the control group 2, the swelling degree of the polymer in the film was increased within a few minutes after attaching to the oral mucosa, and the foreign substance of the formulation was greatly felt. Especially in the case of the control group 2, the initial adhesion was good, but the polymer layer in the film was swollen to protect the protective film. As a result of the detachment, the loss of adhesion and the floating of the oral mucosa appeared, and the foreign substance was added, the discomfort caused by the polymer that fell off, the bitter taste was felt from the formulation, and after separation from the oral mucosa, the polymer layer remained on some oral mucosa. there was.

The present invention has excellent biological adhesion as well as physicochemical aspects such as adhesion, mechanical strength, and adhesion time, and drug dissolution can be sustained. In addition, it provides a very useful oral mucoadhesive film formulation because it is convenient to control and manufacture the film thickness and drying time in the manufacturing process, and because the film formulation is less adhered to the oral mucosa and can be attached for a long time.

Claims (6)

A polyacrylic acid-based polymer, a poloxamer, a cellulose polymer, a drug and a plasticizer that can be absorbed into the oral mucosa, and an adhesion layer as essential components, and a water-insoluble and water-impermeable polymer and a protective layer as essential components, The polyacrylic acid-based polymer and the cellulose-based polymer were 5 to 80% by weight and 5 to 70% by weight of the poloxamer, respectively, based on the total weight of the three types of polymer in the adhesion layer. 5 to 20% by weight of the drug, 0.05 to 20% by weight of the adhesive layer of the plasticizer of 0.1 to 10% by weight, the water-insoluble, water-impermeable polymer in the protective layer is 5 to 50% by weight of the total weight of the protective layer and the protection The plasticizer of the layer has a composition of 0.1 to 10% by weight, the thickness of the film is 30 to 500㎛, characterized in that oral mucoadhesive film preparation. The polyacrylic acid-based polymer according to claim 1 is formed from Carbopol 980, 934, 940, 941, 934P, 971P, 974P, 981, 1342, 1382, 2984, 5984EP or Noveon AA-1, CA-1, CA-2. The poloxamer is at least one selected from, and the poloxamer is at least one selected from poloxamers 124, 188, 338, and 407, and the cellulose polymer is hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl. At least one selected from ethyl cellulose and hydroxypropyl methyl cellulose, and the drug is an oral disease treatment agent such as triamcinolone acetonide or glycyrrhetinic acid, an anti-inflammatory agent such as ketoprofen or pyricampam, diphenhydramine or chloropheniramine and Antihistamines, hormones such as estradiol or testosterone, hypertension drugs such as clonidine or propranolol, such as theophylline or terbutalin Is at least one selected from anesthetic drugs such as bronchodilators, lidocaine, or divcaine, the plasticizer of the adhesion layer is polyethylene glycol, and the water-insoluble and water impermeable polymer is polyester, polyurethane, polyethylene or ethylcellulose, and the protective layer. The plasticizer of the oral mucoadhesive film preparation, characterized in that triethyl citrate. The polyacrylic acid polymer according to claim 2 is at least one selected from Carbopol 934P and 971P, and the poloxamer is at least one selected from poloxamer 188 and 407, and the cellulose polymer is selected from hydroxypropyl ethylcellulose and At least one selected from hydroxypropylmethylcellulose, the drug is an oral disease treatment agent such as triamcinolone acetonide or glycyrrhetinic acid, and the water-insoluble and water-impermeable polymer is polyurethane or ethylcellulose. Film preparation. The blending weight ratio of the poloxamer and the polyacrylic acid polymer and the poloxamer and the cellulose polymer is in the range of 1: 1 to 1: 1.5, respectively, and the water-insoluble and water-impermeable polymer is a protective layer. It is 10-30 weight% of a total weight, and the thickness of a film is 50-300 micrometers, The buccal mucoadhesive film preparation characterized by the above-mentioned. (1) 5 to 80% by weight of polyacrylic acid polymer, 5 to 70% by weight of poloxamer and 5 to 80% by weight of cellulose polymer are dissolved in water and ethanol mixed solvent, Prepare a homogeneous coating solution having a concentration of 5 to 20% by weight of the total weight of the adhesive layer, and then add 0.05 to 20% by weight of the drug and 0.1 to 10% by weight of the plasticizer of the adhesive layer. Dissolving to produce a homogeneous adhesion layer solution; (2) A process for preparing a homogeneous coating solution by dissolving 5 to 50% by weight of water-insoluble and water-impermeable polymer and 0.1 to 10% by weight of a plasticizer of the protective layer separately in ethanol, separately from the step (1). ; (3) removing the internal bubbles from the adhesive layer solution of (1) and applying a coater (Laboratory Drawdown Coater LC-100, Chem Instruments) on a release film and drying to obtain an adhesive layer film; And (4) A process of preparing a film-type oral mucoadhesive film formulation by applying the protective layer solution of (2) to the inside of the adhesive layer film of (3) using a coater and then drying by removing the air bubbles. Method for producing an oral mucoadhesive film formulation comprising a. The weight ratio of poloxamer and polyacrylic acid polymer and poloxamer and cellulose polymer is 1: 1 to 1: 1.5, respectively, and the water insoluble and water impermeable polymer is 10 to 30 weight of the total weight of the protective layer. %, The thickness of the film is 50 to 300㎛ manufacturing method of the oral mucoadhesive film preparation, characterized in that.